期刊文献+

HLA-B*5801携带情况及其与别嘌醇过敏反应间的相关性 被引量:5

HLA-B*5801 carrying station and the correlation of allergic reactions caused by allopurinol
下载PDF
导出
摘要 目的:调查我院住院患者HLA-B*5801等位基因携带情况并研究其与别嘌醇发生过敏反应的相关性。方法:收集2013年5月-10月我院住院部100例患者的相关资料,进行汇总分析和检测其HLA-B*5801等位基因。结果:100例患者中,HLA-B*5801等位基因阳性23例,其中有8例患者发生过敏反应。HLA-B*5801阴性者没有发生过敏反应。结论:我院患者携带HLA-B*5801基因概率高,使用别嘌醇前先检测HLA-B*5801可以更安全地用药。 Objective:To investigate the HLA-B*5801 carrying station and it’s correlation of allergic reac-tions caused by allopurinol of our hospitalized patients. Methods:The patients’ data from inpatient department were collected, then their HLA-B*5801 was analyzed and detected. Results:There were 100 cases determined the HLA-B*58 allele, and the HLA-B*5801 allele positive cases were 23, including 8 cases with allergic reac-tion. HLA-B*5801 negative one did not happen allergic reaction. Conclusion:Our patients carried high rate of HLA-B*5801, it will be more safe to detect the gene in time before use allopurinol. But the association between HLA-B*5801 and allergic reaction caused by allopurinol remains further research.
出处 《温州医学院学报》 CAS 2015年第2期143-145,共3页 Journal of Wenzhou Medical College
关键词 别嘌呤醇 肾功能不全 HLA-B*5801 过敏反应 allopurinol renal insufficiency HLA-B*5801 allergic reaction
  • 相关文献

参考文献13

  • 1Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol[J]. Proc Natl Acad Sci USA, 2005, 102(11): 4134-4139.
  • 2黄玉斌.381例别嘌醇不良反应分析[J].中国药物应用与监测,2005,2(1):32-34. 被引量:23
  • 3Weltzien HU, Moulon C, Martin S, et al. T cell immune re- sponses to haptens.Structural models for allergic and auto- immune reactions[J]. Toxicology, 1996, 107(2): 141-151.
  • 4Pichler WJ. Pharmacological interaction of drugs with anti- gen-specific immune receptors: the p-i concept[J]. Curt Opin Allergy Clin Immunol, 2002, 2(4): 301-305.
  • 5Gerber BO, Pichler WJ. Noncovalent interactions of drugs with immune receptors may mediate drug-induced hyper-sensitivity reactions[J]. AAPS J, 2006, 8(1): E 160-165.
  • 6邓智远,杨健,杨文林.中国大陆汉族别嘌呤醇重症药疹病人HLA-B*5801等位基因的检测[J].皮肤性病诊疗学杂志,2013,20(6):379-382. 被引量:22
  • 7Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. partl: systematic nonpharmacologic and pharmaco- logic therapeutic approaches to hyperuricemia[J]. Arthritis Care Res(Hoboken), 2012, 64(10): 1431-1446.
  • 8Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency[J]. Nephrol Dial Transplant, 2011, 26(11): 3567-3572.
  • 9Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necroly- sis in a Thai population[J]. Pharmacogenet Genomics, 2009, 19(9): 704-709.
  • 10Becker/vIA, Schumacher HR, Espinoza LR, et al. The urate- lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial[J]. Ar- thritis Res Ther, 2010, 12(2): R63.

二级参考文献18

  • 1张圆,王燕燕.别嘌醇致末梢神经炎1例[J].医学研究生学报,1999,12(3):72-72. 被引量:2
  • 2张史昭.别嘌呤醇治疗痛风性肾病致药物反应3例[J].临床荟萃,1994,9(20):937-938. 被引量:1
  • 3郭燕妮.别嘌呤醇所致药疹1例[J].海峡药学,1995,7(3):113-113. 被引量:3
  • 4Bunce M, Baruardo MC, Welsh KI. The PCR-SSP Man- ager computer program: a tool for maintaining sequence alignments and automatically updating the specifieities of PCR-SSP primers and primer mixes [ J]. Tissue Anti- gens, 1998, 52(2): 158-174.
  • 5Nassif A, Bensussan A, Boumsell L, et al. Toxic epider- mal necrolysis: effector cells are drug-specific cytotoxic T cells [ J ]. J Allergy Clin Immunol, 2004, 114 ( 5 ) : 1209-1215.
  • 6Hung SI, Chung WH, Liou LB, et al. HLA-B^*5801 al- lele as a genetic marker for severe cutaneous adverse re- actions caused by allopurinol [ J ]. Proc Natl Acad Sei U S A, 2005, 102(11): 4134-4139.
  • 7Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B * 5801 and allopurinol- induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population [ J ]. Pharmacogenet Ge- nomics, 2009, 19(9) : 704-709.
  • 8Lonjou C, Thomas L, Borot N, et al. A marker for Ste- vens-Johnson syndrome : ethnicity matters [ J ]. Pharma- cogenomics J, 2006, 6(4): 265-268.
  • 9向丹黎,张林.别嘌呤醇致重型药疹合并恶性组织细胞病1例死亡分析[J].华西医学,2000,15(1):108-108. 被引量:5
  • 10邓智远,杨健.别嘌醇严重不良反应的药物遗传学研究进展[J].临床皮肤科杂志,2013,42(4):262-264. 被引量:9

共引文献43

同被引文献32

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部